Baidu
map

贝伐珠单抗与转移性结直肠癌患者ATE有关

2011-08-17 MedSci原创 MedSci原创

来源:医学论坛网   《肿瘤学年鉴》(Ann Oncol)近期发表的一项研究表明,贝伐珠单抗治疗与转移性结直肠癌动脉血栓栓塞形成(ATE)风险较高有关,但在老年患者或伴有ATE病史或血管风险因素的患者中,贝伐珠单抗的安全性并不显著更差。此外,研究未能在接受贝伐单抗的患者中证明阿司匹林对ATE的预防作用。   该研究来自MAX研究的471例转移性结直肠癌患者的3、4或5级ATE事件和其

来源:医学论坛网

  《肿瘤学年鉴》(Ann Oncol)近期发表的一项研究表明,贝伐珠单抗治疗与转移性结直肠癌动脉血栓栓塞形成(ATE)风险较高有关,但在老年患者或伴有ATE病史或血管风险因素的患者中,贝伐珠单抗的安全性并不显著更差。此外,研究未能在接受贝伐单抗的患者中证明阿司匹林对ATE的预防作用。

  该研究来自MAX研究的471例转移性结直肠癌患者的3、4或5级ATE事件和其他数据(包括年龄、基线心血管风险因素、ATE病史和阿司匹林使用情况)。

  结果显示,接受贝伐珠单抗治疗的患者3、4或5 级ATE的发生率为3.8%。 年龄>65岁的患者、有ATE病史的患者和伴心血管风险因素患者的ATE发生率分别为2.1%、5%和5%。年龄、ATE病史或心血管风险因素并没有增加ATE风险。阿司匹林使用者ATE发生率高于未使用者(8.9% 对 2.7%),但伴有心血管风险因素患者的比例较高。

相关链接:Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954779, encodeId=48531954e79b7, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Mar 02 15:35:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386069, encodeId=d5e71386069c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452562, encodeId=478c1452562d8, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476907, encodeId=5e2e14e690794, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1954779, encodeId=48531954e79b7, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Mar 02 15:35:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386069, encodeId=d5e71386069c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452562, encodeId=478c1452562d8, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476907, encodeId=5e2e14e690794, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1954779, encodeId=48531954e79b7, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Mar 02 15:35:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386069, encodeId=d5e71386069c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452562, encodeId=478c1452562d8, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476907, encodeId=5e2e14e690794, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1954779, encodeId=48531954e79b7, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Fri Mar 02 15:35:00 CST 2012, time=2012-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386069, encodeId=d5e71386069c3, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452562, encodeId=478c1452562d8, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476907, encodeId=5e2e14e690794, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Fri Aug 19 07:35:00 CST 2011, time=2011-08-19, status=1, ipAttribution=)]

相关资讯

贝伐珠单抗缓解难治性卵巢颗粒细胞瘤患者的症状

引言        近期对于贝伐珠单抗用于卵巢恶性肿瘤的研究集中在上皮恶性肿瘤中[1]。关于贝伐珠单抗用于治疗性索肿瘤,如卵巢颗粒细胞瘤的潜在作用未有评估。在此,我们报道一例难治性卵巢颗粒细胞瘤患者经贝伐珠单抗治疗后腹水症状得到缓解。 病例介绍       

Baidu
map
Baidu
map
Baidu
map